Tag Archives: eliminate

#437209 A Renaissance of Genomics and Drugs Is ...

Posted on June 26, 2020 by Android

The causes of aging are extremely complex and unclear. But with longevity clinical trials increasing, more answers—and questions—are emerging than ever before.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

In this article, I’ll explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.

Genome Sequencing and Editing
Your genome is the software that runs your body. A sequence of 3.2 billion letters makes you “you.” These base pairs of A’s, T’s, C’s, and G’s determine your hair color, your height, your personality, your propensity for disease, your lifespan, and so on.

Until recently, it’s been very difficult to rapidly and cheaply “read” these letters—and even more difficult to understand what they mean. Since 2001, the cost to sequence a whole human genome has plummeted exponentially, outpacing Moore’s Law threefold. From an initial cost of $3.7 billion, it dropped to $10 million in 2006, and to $1,500 in 2015.

Today, the cost of genome sequencing has dropped below $600, and according to Illumina, the world’s leading sequencing company, the process will soon cost about $100 and take about an hour to complete.

This represents one of the most powerful and transformative technology revolutions in healthcare. When we understand your genome, we’ll be able to understand how to optimize “you.”

We’ll know the perfect foods, the perfect drugs, the perfect exercise regimen, and the perfect supplements, just for you.
We’ll understand what microbiome types, or gut flora, are ideal for you (more on this in a later article).
We’ll accurately predict how specific sedatives and medicines will impact you.
We’ll learn which diseases and illnesses you’re most likely to develop and, more importantly, how to best prevent them from developing in the first place (rather than trying to cure them after the fact).

CRISPR Gene Editing
In addition to reading the human genome, scientists can now edit a genome using a naturally occurring biological system discovered in 1987 called CRISPR/Cas9.

Short for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9, the editing system was adapted from a naturally-occurring defense system found in bacteria.

Here’s how it works. The bacteria capture snippets of DNA from invading viruses (or bacteriophage) and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to “remember” the viruses (or closely related ones), and defend against future invasions. If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses’ DNA. The bacteria then use Cas9 to cut the DNA apart, which disables the virus.

Most importantly, CRISPR is cheap, quick, easy to use, and more accurate than all previous gene editing methods. As a result, CRISPR/Cas9 has swept through labs around the world as the way to edit a genome. A short search in the literature will show an exponential rise in the number of CRISPR-related publications and patents.

2018: Filled With CRISPR Breakthroughs
Early results are impressive. Researchers have used CRISPR to genetically engineer cocaine resistance into mice, reverse the gene defect causing Duchenne muscular dystrophy (DMD) in dogs, and reduce genetic deafness in mice.

Already this year, CRISPR-edited immune cells have been shown to successfully kill cancer cells in human patients. Researchers have discovered ways to activate CRISPR with light and use the gene-editing technology to better understand Alzheimer’s disease progression.

With great power comes great responsibility, and the opportunity for moral and ethical dilemmas. In 2015, Chinese scientists sparked global controversy when they first edited human embryo cells in the lab with the goal of modifying genes that would make the child resistant to smallpox, HIV, and cholera. Three years later, in November 2018, researcher He Jiankui informed the world that the first set of CRISPR-engineered female twins had been delivered.

To accomplish his goal, Jiankui deleted a region of a receptor on the surface of white blood cells known as CCR5, introducing a rare, natural genetic variation that makes it more difficult for HIV to infect its favorite target, white blood cells. Because Jiankui forged ethical review documents and misled doctors in the process, he was sentenced to three years in prison and fined $429,000 last December.

Coupled with significant ethical conversations necessary for progress, CRISPR will soon provide us the tools to eliminate diseases, create hardier offspring, produce new environmentally resistant crops, and even wipe out pathogens.

Senolytics, Nutraceuticals, and Pharmaceuticals
Over the arc of your life, the cells in your body divide until they reach what is known as the Hayflick limit, or the number of times a normal human cell population will divide before cell division stops, which is typically about 50 divisions.

What normally follows next is programmed cell death or destruction by the immune system. A very small fraction of cells, however, become senescent cells and evade this fate to linger indefinitely. These lingering cells secrete a potent mix of molecules that triggers chronic inflammation, damages the surrounding tissue structures, and changes the behavior of nearby cells for the worse. Senescent cells appear to be one of the root causes of aging, causing everything from fibrosis and blood vessel calcification to localized inflammatory conditions such as osteoarthritis to diminished lung function.

Fortunately, both the scientific and entrepreneurial communities have begun to work on senolytic therapies, moving the technology for selectively destroying senescent cells out of the laboratory and into a half-dozen startup companies.

Prominent companies in the field include the following:

Unity Biotechnology is developing senolytic medicines to selectively eliminate senescent cells with an initial focus on delivering localized therapy in osteoarthritis, ophthalmology, and pulmonary disease.

Oisin Biotechnologies is pioneering a programmable gene therapy that can destroy cells based on their internal biochemistry.

SIWA Therapeutics is working on an immunotherapy approach to the problem of senescent cells.

In recent years, researchers have identified or designed a handful of senolytic compounds that can curb aging by regulating senescent cells. Two of these drugs that have gained mainstay research traction are rapamycin and metformin.

(1) Rapamycin

Originally extracted from bacteria found on Easter Island, rapamycin acts on the m-TOR (mechanistic target of rapamycin) pathway to selectively block a key protein that facilitates cell division. Currently, rapamycin derivatives are widely used for immunosuppression in organ and bone marrow transplants. Research now suggests that use results in prolonged lifespan and enhanced cognitive and immune function.

PureTech Health subsidiary resTORbio (which went public in 2018) is working on a rapamycin-based drug intended to enhance immunity and reduce infection. Their clinical-stage RTB101 drug works by inhibiting part of the mTOR pathway.

Results of the drug’s recent clinical trial include decreased incidence of infection, improved influenza vaccination response, and a 30.6 percent decrease in respiratory tract infection.

Impressive, to say the least.

(2) Metformin

Metformin is a widely-used generic drug for mitigating liver sugar production in Type 2 diabetes patients. Researchers have found that metformin also reduces oxidative stress and inflammation, which otherwise increase as we age. There is strong evidence that metformin can augment cellular regeneration and dramatically mitigate cellular senescence by reducing both oxidative stress and inflammation.

Over 100 studies registered on ClinicalTrials.gov are currently following up on strong evidence of metformin’s protective effect against cancer.

(3) Nutraceuticals and NAD+

Beyond cellular senescence, certain critical nutrients and proteins tend to decline as a function of age. Nutraceuticals combat aging by supplementing and replenishing these declining nutrient levels.

NAD+ exists in every cell, participating in every process from DNA repair to creating the energy vital for cellular processes. It’s been shown that NAD+ levels decline as we age.

The Elysium Health Basis supplement aims to elevate NAD+ levels in the body to extend one’s lifespan. Elysium’s first clinical study reports that Basis increases NAD+ levels consistently by a sustained 40 percent.

Conclusion
These are just a taste of the tremendous momentum that longevity and aging technology has right now. As artificial intelligence and quantum computing transform how we decode our DNA and how we discover drugs, genetics and pharmaceuticals will become truly personalized.

The next article in this series will demonstrate how artificial intelligence is converging with genetics and pharmaceuticals to transform how we approach longevity, aging, and vitality.

We are edging closer toward a dramatically extended healthspan—where 100 is the new 60. What will you create, where will you explore, and how will you spend your time if you are able to add an additional 40 healthy years to your life?

Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”

If you’d like to learn more and consider joining our 2021 membership, apply here.

(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)

This article originally appeared on diamandis.com. Read the original article here.

Image Credit: Arek Socha from Pixabay Continue reading →

Posted in Human Robots

#437103 How to Make Sense of Uncertainty in a ...

Posted on May 1, 2020 by Android

As the internet churns with information about Covid-19, about the virus that causes the disease, and about what we’re supposed to do to fight it, it can be difficult to see the forest for the trees. What can we realistically expect for the rest of 2020? And how do we even know what’s realistic?

Today, humanity’s primary, ideal goal is to eliminate the virus, SARS-CoV-2, and Covid-19. Our second-choice goal is to control virus transmission. Either way, we have three big aims: to save lives, to return to public life, and to keep the economy functioning.

To hit our second-choice goal—and maybe even our primary goal—countries are pursuing five major public health strategies. Note that many of these advances cross-fertilize: for example, advances in virus testing and antibody testing will drive data-based prevention efforts.

Five major public health strategies are underway to bring Covid-19 under control and to contain the spread of SARS-CoV-2.
These strategies arise from things we can control based on the things that we know at any given moment. But what about the things we can’t control and don’t yet know?

The biology of the virus and how it interacts with our bodies is what it is, so we should seek to understand it as thoroughly as possible. How long any immunity gained from prior infection lasts—and indeed whether people develop meaningful immunity at all after infection—are open questions urgently in need of greater clarity. Similarly, right now it’s important to focus on understanding rather than making assumptions about environmental factors like seasonality.

But the biggest question on everyone’s lips is, “When?” When will we see therapeutic progress against Covid-19? And when will life get “back to normal”? There are lots of models out there on the internet; which of those models are right? The simple answer is “none of them.” That’s right—it’s almost certain that every model you’ve seen is wrong in at least one detail, if not all of them. But modeling is meant to be a tool for deeper thinking, a way to run mental (and computational) experiments before—and while—taking action. As George E. P. Box famously wrote in 1976, “All models are wrong, but some are useful.”

Here, we’re seeking useful insights, as opposed to exact predictions, which is why we’re pulling back from quantitative details to get at the mindsets that will support agency and hope. To that end, I’ve been putting together timelines that I believe will yield useful expectations for the next year or two—and asking how optimistic I need to be in order to believe a particular timeline.

For a moderately optimistic scenario to be relevant, breakthroughs in science and technology come at paces expected based on previous efforts and assumptions that turn out to be basically correct; accessibility of those breakthroughs increases at a reasonable pace; regulation achieves its desired effects, without major surprises; and compliance with regulations is reasonably high.

In contrast, if I’m being highly optimistic, breakthroughs in science and technology and their accessibility come more quickly than they ever have before; regulation is evidence-based and successful in the first try or two; and compliance with those regulations is high and uniform. If I’m feeling not-so-optimistic, then I anticipate serious setbacks to breakthroughs and accessibility (with the overturning of many important assumptions), repeated failure of regulations to achieve their desired outcomes, and low compliance with those regulations.

The following scenarios outline the things that need to happen in the fight against Covid-19, when I expect to see them, and how confident I feel in those expectations. They focus on North America and Europe because there are data missing about China’s 2019 outbreak and other regions are still early in their outbreaks. Perhaps the most important thing to keep in mind throughout: We know more today than we did yesterday, but we still have much to learn. New knowledge derived from greater study and debate will almost certainly inspire ongoing course corrections.

As you dive into the scenarios below, practice these three mindset shifts. First, defeating Covid-19 will be a marathon, not a sprint. We shouldn’t expect life to look like 2019 for the next year or two—if ever. As Ed Yong wrote recently in The Atlantic, “There won’t be an obvious moment when everything is under control and regular life can safely resume.” Second, remember that you have important things to do for at least a year. And third, we are all in this together. There is no “us” and “them.” We must all be alert, responsive, generous, and strong throughout 2020 and 2021—and willing to throw away our assumptions when scientific evidence invalidates them.

The Middle Way: Moderate Optimism
Let’s start with the case in which I have the most confidence: moderate optimism.

This timeline considers milestones through late 2021, the earliest that I believe vaccines will become available. The “normal” timeline for developing a vaccine for diseases like seasonal flu is 18 months, which leads to my projection that we could potentially have vaccines as soon as 18 months from the first quarter of 2020. While Melinda Gates agrees with that projection, others (including AI) believe that 3 to 5 years is far more realistic, based on past vaccine development and the need to test safety and efficacy in humans. However, repurposing existing vaccines against other diseases—or piggybacking off clever synthetic platforms—could lead to vaccines being available sooner. I tried to balance these considerations for this moderately optimistic scenario. Either way, deploying vaccines at the end of 2021 is probably much later than you may have been led to believe by the hype engine. Again, if you take away only one message from this article, remember that the fight against Covid-19 is a marathon, not a sprint.

Here, I’ve visualized a moderately optimistic scenario as a baseline. Think of these timelines as living guides, as opposed to exact predictions. There are still many unknowns. More or less optimistic views (see below) and new information could shift these timelines forward or back and change the details of the strategies.
Based on current data, I expect that the first wave of Covid-19 cases (where we are now) will continue to subside in many areas, leading governments to ease restrictions in an effort to get people back to work. We’re already seeing movement in that direction, with a variety of benchmarks and changes at state and country levels around the world. But depending on the details of the changes, easing restrictions will probably cause a second wave of sickness (see Germany and Singapore), which should lead governments to reimpose at least some restrictions.

In tandem, therapeutic efforts will be transitioning from emergency treatments to treatments that have been approved based on safety and efficacy data in clinical trials. In a moderately optimistic scenario, assuming clinical trials currently underway yield at least a few positive results, this shift to mostly approved therapies could happen as early as the third or fourth quarter of this year and continue from there. One approval that should come rather quickly is for plasma therapies, in which the blood from people who have recovered from Covid-19 is used as a source of antibodies for people who are currently sick.

Companies around the world are working on both viral and antibody testing, focusing on speed, accuracy, reliability, and wide accessibility. While these tests are currently being run in hospitals and research laboratories, at-home testing is a critical component of the mass testing we’ll need to keep viral spread in check. These are needed to minimize the impact of asymptomatic cases, test the assumption that infection yields resistance to subsequent infection (and whether it lasts), and construct potential immunity passports if this assumption holds. Testing is also needed for contact tracing efforts to prevent further spread and get people back to public life. Finally, it’s crucial to our fundamental understanding of the biology of SARS-CoV-2 and Covid-19.

We need tests that are very reliable, both in the clinic and at home. So, don’t go buying any at-home test kits just yet, even if you find them online. Wait for reliable test kits and deeper understanding of how a test result translates to everyday realities. If we’re moderately optimistic, in-clinic testing will rapidly expand this quarter and/or next, with the possibility of broadly available, high-quality at-home sampling (and perhaps even analysis) thereafter.

Note that testing is not likely to be a “one-and-done” endeavor, as a person’s infection and immunity status change over time. Expect to be testing yourself—and your family—often as we move later into 2020.

Testing data are also going to inform distancing requirements at the country and local levels. In this scenario, restrictions—at some level of stringency—could persist at least through the end of 2020, as most countries are way behind the curve on testing (Iceland is an informative exception). Governments will likely continue to ask citizens to work from home if at all possible; to wear masks or face coverings in public; to employ heightened hygiene and social distancing in workplaces; and to restrict travel and social gatherings. So while it’s likely we’ll be eating in local restaurants again in 2020 in this scenario, at least for a little while, it’s not likely we’ll be heading to big concerts any time soon.

The Extremes: High and Low Optimism
How would high and low levels of optimism change our moderately optimistic timeline? The milestones are the same, but the time required to achieve them is shorter or longer, respectively. Quantifying these shifts is less important than acknowledging and incorporating a range of possibilities into our view. It pays to pay attention to our bias. Here are a few examples of reasonable possibilities that could shift the moderately optimistic timeline.

When vaccines become available
Vaccine repurposing could shorten the time for vaccines to become available; today, many vaccine candidates are in various stages of testing. On the other hand, difficulties in manufacture and distribution, or faster-than-expected mutation of SARS-CoV-2, could slow vaccine development. Given what we know now, I am not strongly concerned about either of these possibilities—drug companies are rapidly expanding their capabilities, and viral mutation isn’t an urgent concern at this time based on sequencing data—but they could happen.

At first, governments will likely supply vaccines to essential workers such as healthcare workers, but it is essential that vaccines become widely available around the world as quickly and as safely as possible. Overall, I suggest a dose of skepticism when reading highly optimistic claims about a vaccine (or multiple vaccines) being available in 2020. Remember, a vaccine is a knockout punch, not a first line of defense for an outbreak.

When testing hits its stride
While I am confident that testing is a critical component of our response to Covid-19, reliability is incredibly important to testing for SARS-CoV-2 and for immunity to the disease, particularly at home. For an individual, a false negative (being told you don’t have antibodies when you really do) could be just as bad as a false positive (being told you do have antibodies when you really don’t). Those errors are compounded when governments are trying to make evidence-based policies for social and physical distancing.

If you’re highly optimistic, high-quality testing will ramp up quickly as companies and scientists innovate rapidly by cleverly combining multiple test modalities, digital signals, and cutting-edge tech like CRISPR. Pop-up testing labs could also take some pressure off hospitals and clinics.

If things don’t go well, reliability issues could hinder testing, manufacturing bottlenecks could limit availability, and both could hamstring efforts to control spread and ease restrictions. And if it turns out that immunity to Covid-19 isn’t working the way we assumed, then we must revisit our assumptions about our path(s) back to public life, as well as our vaccine-development strategies.

How quickly safe and effective treatments appear
Drug development is known to be long, costly, and fraught with failure. It’s not uncommon to see hope in a drug spike early only to be dashed later on down the road. With that in mind, the number of treatments currently under investigation is astonishing, as is the speed through which they’re proceeding through testing. Breakthroughs in a therapeutic area—for example in treating the seriously ill or in reducing viral spread after an infection takes hold—could motivate changes in the focus of distancing regulations.

While speed will save lives, we cannot overlook the importance of knowing a treatment’s efficacy (does it work against Covid-19?) and safety (does it make you sick in a different, or worse, way?). Repurposing drugs that have already been tested for other diseases is speeding innovation here, as is artificial intelligence.

Remarkable collaborations among governments and companies, large and small, are driving innovation in therapeutics and devices such as ventilators for treating the sick.

Whether government policies are effective and responsive
Those of us who have experienced lockdown are eager for it to be over. Businesses, economists, and governments are also eager to relieve the terrible pressure that is being exerted on the global economy. However, lifting restrictions will almost certainly lead to a resurgence in sickness.

Here, the future is hard to model because there are many, many factors at play, and at play differently in different places—including the extent to which individuals actually comply with regulations.

Reliable testing—both in the clinic and at home—is crucial to designing and implementing restrictions, monitoring their effectiveness, and updating them; delays in reliable testing could seriously hamper this design cycle. Lack of trust in governments and/or companies could also suppress uptake. That said, systems are already in place for contact tracing in East Asia. Other governments could learn important lessons, but must also earn—and keep—their citizens’ trust.

Expect to see restrictions descend and then lift in response to changes in the number of Covid-19 cases and in the effectiveness of our prevention strategies. Also expect country-specific and perhaps even area-specific responses that differ from each other. The benefit of this approach? Governments around the world are running perhaps hundreds of real-time experiments and design cycles in balancing health and the economy, and we can learn from the results.

A Way Out
As Jeremy Farrar, head of the Wellcome Trust, told Science magazine, “Science is the exit strategy.” Some of our greatest technological assistance is coming from artificial intelligence, digital tools for collaboration, and advances in biotechnology.

Our exit strategy also needs to include empathy and future visioning—because in the midst of this crisis, we are breaking ground for a new, post-Covid future.

What do we want that future to look like? How will the hard choices we make now about data ethics impact the future of surveillance? Will we continue to embrace inclusiveness and mass collaboration? Perhaps most importantly, will we lay the foundation for successfully confronting future challenges? Whether we’re thinking about the next pandemic (and there will be others) or the cascade of catastrophes that climate change is bringing ever closer—it’s important to remember that we all have the power to become agents of that change.

Special thanks to Ola Kowalewski and Jason Dorrier for significant conversations.

Image Credit: Drew Beamer / Unsplash Continue reading →

Posted in Human Robots

#436207 This Week’s Awesome Tech Stories From ...

Posted on November 23, 2019 by Android

COMPUTING
A Giant Superfast AI Chip Is Being Used to Find Better Cancer Drugs
Karen Hao | MIT Technology Review
“Thus far, Cerebras’s computer has checked all the boxes. Thanks to its chip size—it is larger than an iPad and has 1.2 trillion transistors for making calculations—it isn’t necessary to hook multiple smaller processors together, which can slow down model training. In testing, it has already shrunk the training time of models from weeks to hours.”

MEDICINE
Humans Put Into Suspended Animation for First Time
Ian Sample | The Guardian
“The process involves rapidly cooling the brain to less than 10C by replacing the patient’s blood with ice-cold saline solution. Typically the solution is pumped directly into the aorta, the main artery that carries blood away from the heart to the rest of the body.”

DRONES
This Transforming Drone Can Be Fired Straight Out of a Cannon
James Vincent | The Verge
“Drones are incredibly useful machines in the air, but getting them up and flying can be tricky, especially in crowded, windy, or emergency scenarios when speed is a factor. But a group of researchers from Caltech university and NASA’s Jet Propulsion Laboratory have come up with an elegant and oh-so-fun solution: fire the damn thing out of a cannon.”

ROBOTICS
Alphabet’s Dream of an ‘Everyday Robot’ Is Just Out of Reach
Tom Simonite | Wired
“Sorting trash was chosen as a convenient challenge to test the project’s approach to creating more capable robots. It’s using artificial intelligence software developed in collaboration with Google to make robots that learn complex tasks through on-the-job experience. The hope is to make robots less reliant on human coding for their skills, and capable of adapting quickly to complex new tasks and environments.”

ENVIRONMENT
The Electric Car Revolution May Take a Lot Longer Than Expected
James Temple | MIT Technology Review
“A new report from the MIT Energy Initiative warns that EVs may never reach the same sticker price so long as they rely on lithium-ion batteries, the energy storage technology that powers most of today’s consumer electronics. In fact, it’s likely to take another decade just to eliminate the difference in the lifetime costs between the vehicle categories, which factors in the higher fuel and maintenance expenses of standard cars and trucks.”

SPACE
How Two Intruders From Interstellar Space Are Upending Astronomy
Alexandra Witze | Nature
“From the tallest peak in Hawaii to a high plateau in the Andes, some of the biggest telescopes on Earth will point towards a faint smudge of light over the next few weeks. …What they’re looking for is a rare visitor that is about to make its closest approach to the Sun. After that, they have just months to grab as much information as they can from the object before it disappears forever into the blackness of space.”

Image Credit: Simone Hutsch / Unsplash Continue reading →

Posted in Human Robots

#436079 Video Friday: This Humanoid Robot Will ...

Posted on October 11, 2019 by Android

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

Northeast Robotics Colloquium – October 12, 2019 – Philadelphia, Pa., USA
Ro-Man 2019 – October 14-18, 2019 – New Delhi, India
Humanoids 2019 – October 15-17, 2019 – Toronto, Canada
ARSO 2019 – October 31-1, 2019 – Beijing, China
ROSCon 2019 – October 31-1, 2019 – Macau
IROS 2019 – November 4-8, 2019 – Macau
Let us know if you have suggestions for next week, and enjoy today’s videos.

What’s better than a robotics paper with “dynamic” in the title? A robotics paper with “highly dynamic” in the title. From Sangbae Kim’s lab at MIT, the latest exploits of Mini Cheetah:

Yes I’d very much like one please. Full paper at the link below.

[ Paper ] via [ MIT ]

A humanoid robot serving you ice cream—on his own ice cream bike: What a delicious vision!

[ Roboy ]

The Roomba “i” series and “s” series vacuums have just gotten an update that lets you set “keep out” zones, which is super useful. Tell your robot where not to go!

I feel bad, that Roomba was probably just hungry 🙁

[ iRobot ]

We wrote about Voliro’s tilt-rotor hexcopter a couple years ago, and now it’s off doing practical things, like spray painting a building pretty much the same color that it was before.

[ Voliro ]

Thanks Mina!

Here’s a clever approach for bin-picking problematic objects, like shiny things: Just grab a whole bunch, and then sort out what you need on a nice robot-friendly table.

It might take a little bit longer, but what do you care, you’re probably off sipping a cocktail with a little umbrella in it on a beach somewhere.

[ Harada Lab ]

A unique combination of the IRB 1200 and YuMi industrial robots that use vision, AI and deep learning to recognize and categorize trash for recycling.

[ ABB ]

Measuring glacial movements in-situ is a challenging, but necessary task to model glaciers and predict their future evolution. However, installing GPS stations on ice can be dangerous and expensive when not impossible in the presence of large crevasses. In this project, the ASL develops UAVs for dropping and recovering lightweight GPS stations over inaccessible glaciers to record the ice flow motion. This video shows the results of first tests performed at Gorner glacier, Switzerland, in July 2019.

[ EPFL ]

Turns out Tertills actually do a pretty great job fighting weeds.

Plus, they leave all those cute lil’ Tertill tracks.

[ Franklin Robotics ]

The online autonomous navigation and semantic mapping experiment presented [below] is conducted with the Cassie Blue bipedal robot at the University of Michigan. The sensors attached to the robot include an IMU, a 32-beam LiDAR and an RGB-D camera. The whole online process runs in real-time on a Jetson Xavier and a laptop with an i7 processor.

The resulting map is so precise that it looks like we are doing real-time SLAM (simultaneous localization and mapping). In fact, the map is based on dead-reckoning via the InvEKF.

[ GTSAM ] via [ University of Michigan ]

UBTECH has announced an upgraded version of its Meebot, which is 30 percent bigger and comes with more sensors and programmable eyes.

[ UBTECH ]

ABB’s research team will be working with medical staff, scientist and engineers to develop non-surgical medical robotics systems, including logistics and next-generation automated laboratory technologies. The team will develop robotics solutions that will help eliminate bottlenecks in laboratory work and address the global shortage of skilled medical staff.

[ ABB ]

In this video, Ian and Chris go through Misty’s SDK, discussing the languages we’ve included, the tools that make it easy for you to get started quickly, a quick rundown of how to run the skills you build, plus what’s ahead on the Misty SDK roadmap.

[ Misty Robotics ]

My guess is that this was not one of iRobot’s testing environments for the Roomba.

You know, that’s actually super impressive. And maybe if they threw one of the self-emptying Roombas in there, it would be a viable solution to the entire problem.

[ How Farms Work ]

Part of WeRobotics’ Flying Labs network, Panama Flying Labs is a local knowledge hub catalyzing social good and empowering local experts. Through training and workshops, demonstrations and missions, the Panama Flying Labs team leverages the power of drones, data, and AI to promote entrepreneurship, build local capacity, and confront the pressing social challenges faced by communities in Panama and across Central America.

[ Panama Flying Labs ]

Go on a virtual flythrough of the NIOSH Experimental Mine, one of two courses used in the recent DARPA Subterranean Challenge Tunnel Circuit Event held 15-22 August, 2019. The data used for this partial flythrough tour were collected using 3D LIDAR sensors similar to the sensors commonly used on autonomous mobile robots.

[ SubT ]

Special thanks to PBS, Mark Knobil, Joe Seamans and Stan Brandorff and many others who produced this program in 1991.

It features Reid Simmons (and his 1 year old son), David Wettergreen, Red Whittaker, Mac Macdonald, Omead Amidi, and other Field Robotics Center alumni building the planetary walker prototype called Ambler. The team gets ready for an important demo for NASA.

[ CMU RI ]

As art and technology merge, roboticist Madeline Gannon explores the frontiers of human-robot interaction across the arts, sciences and society, and explores what this could mean for the future.

[ Sonar+D ] Continue reading →

Posted in Human Robots

#435436 Undeclared Wars in Cyberspace Are ...

Posted on August 1, 2019 by Android

The US is at war. That’s probably not exactly news, as the country has been engaged in one type of conflict or another for most of its history. The last time we officially declared war was after Japan bombed Pearl Harbor in December 1941.

Our biggest undeclared war today is not being fought by drones in the mountains of Afghanistan or even through the less-lethal barrage of threats over the nuclear programs in North Korea and Iran. In this particular war, it is the US that is under attack and on the defensive.

This is cyberwarfare.

The definition of what constitutes a cyber attack is a broad one, according to Greg White, executive director of the Center for Infrastructure Assurance and Security (CIAS) at The University of Texas at San Antonio (UTSA).

At the level of nation-state attacks, cyberwarfare could involve “attacking systems during peacetime—such as our power grid or election systems—or it could be during war time in which case the attacks may be designed to cause destruction, damage, deception, or death,” he told Singularity Hub.

For the US, the Pearl Harbor of cyberwarfare occurred during 2016 with the Russian interference in the presidential election. However, according to White, an Air Force veteran who has been involved in computer and network security since 1986, the history of cyber war can be traced back much further, to at least the first Gulf War of the early 1990s.

“We started experimenting with cyber attacks during the first Gulf War, so this has been going on a long time,” he said. “Espionage was the prime reason before that. After the war, the possibility of expanding the types of targets utilized expanded somewhat. What is really interesting is the use of social media and things like websites for [psychological operation] purposes during a conflict.”

The 2008 conflict between Russia and the Republic of Georgia is often cited as a cyberwarfare case study due to the large scale and overt nature of the cyber attacks. Russian hackers managed to bring down more than 50 news, government, and financial websites through denial-of-service attacks. In addition, about 35 percent of Georgia’s internet networks suffered decreased functionality during the attacks, coinciding with the Russian invasion of South Ossetia.

The cyberwar also offers lessons for today on Russia’s approach to cyberspace as a tool for “holistic psychological manipulation and information warfare,” according to a 2018 report called Understanding Cyberwarfare from the Modern War Institute at West Point.

US Fights Back
News in recent years has highlighted how Russian hackers have attacked various US government entities and critical infrastructure such as energy and manufacturing. In particular, a shadowy group known as Unit 26165 within the country’s military intelligence directorate is believed to be behind the 2016 US election interference campaign.

However, the US hasn’t been standing idly by. Since at least 2012, the US has put reconnaissance probes into the control systems of the Russian electric grid, The New York Times reported. More recently, we learned that the US military has gone on the offensive, putting “crippling malware” inside the Russian power grid as the U.S. Cyber Command flexes its online muscles thanks to new authority granted to it last year.

“Access to the power grid that is obtained now could be used to shut something important down in the future when we are in a war,” White noted. “Espionage is part of the whole program. It is important to remember that cyber has just provided a new domain in which to conduct the types of activities we have been doing in the real world for years.”

The US is also beginning to pour more money into cybersecurity. The 2020 fiscal budget calls for spending $17.4 billion throughout the government on cyber-related activities, with the Department of Defense (DoD) alone earmarked for $9.6 billion.

Despite the growing emphasis on cybersecurity in the US and around the world, the demand for skilled security professionals is well outpacing the supply, with a projected shortfall of nearly three million open or unfilled positions according to the non-profit IT security organization (ISC)².

UTSA is rare among US educational institutions in that security courses and research are being conducted across three different colleges, according to White. About 10 percent of the school’s 30,000-plus students are enrolled in a cyber-related program, he added, and UTSA is one of only 21 schools that has received the Cyber Operations Center of Excellence designation from the National Security Agency.

“This track in the computer science program is specifically designed to prepare students for the type of jobs they might be involved in if they went to work for the DoD,” White said.

However, White is extremely doubtful there will ever be enough cyber security professionals to meet demand. “I’ve been preaching that we’ve got to worry about cybersecurity in the workforce, not just the cybersecurity workforce, not just cybersecurity professionals. Everybody has a responsibility for cybersecurity.”

Artificial Intelligence in Cybersecurity
Indeed, humans are often seen as the weak link in cybersecurity. That point was driven home at a cybersecurity roundtable discussion during this year’s Brainstorm Tech conference in Aspen, Colorado.

Participant Dorian Daley, general counsel at Oracle, said insider threats are at the top of the list when it comes to cybersecurity. “Sadly, I think some of the biggest challenges are people, and I mean that in a number of ways. A lot of the breaches really come from insiders. So the more that you can automate things and you can eliminate human malicious conduct, the better.”

White noted that automation is already the norm in cybersecurity. “Humans can’t react as fast as systems can launch attacks, so we need to rely on automated defenses as well,” he said. “This doesn’t mean that humans are not in the loop, but much of what is done these days is ‘scripted’.”

The use of artificial intelligence, machine learning, and other advanced automation techniques have been part of the cybersecurity conversation for quite some time, according to White, such as pattern analysis to look for specific behaviors that might indicate an attack is underway.

“What we are seeing quite a bit of today falls under the heading of big data and data analytics,” he explained.

But there are signs that AI is going off-script when it comes to cyber attacks. In the hands of threat groups, AI applications could lead to an increase in the number of cyberattacks, wrote Michelle Cantos, a strategic intelligence analyst at cybersecurity firm FireEye.

“Current AI technology used by businesses to analyze consumer behavior and find new customer bases can be appropriated to help attackers find better targets,” she said. “Adversaries can use AI to analyze datasets and generate recommendations for high-value targets they think the adversary should hit.”

In fact, security researchers have already demonstrated how a machine learning system could be used for malicious purposes. The Social Network Automated Phishing with Reconnaissance system, or SNAP_R, generated more than four times as many spear-phishing tweets on Twitter than a human—and was just as successful at targeting victims in order to steal sensitive information.

Cyber war is upon us. And like the current war on terrorism, there are many battlefields from which the enemy can attack and then disappear. While total victory is highly unlikely in the traditional sense, innovations through AI and other technologies can help keep the lights on against the next cyber attack.

Image Credit: pinkeyes / Shutterstock.com Continue reading →

Posted in Human Robots